Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress
Authors
Michael Nyquist•Alexandra Corella•Peter Nelson
Journal
Cell Reports
Published
May 1, 2020
Sign in to comment
Add a comment...